Related references
Note: Only part of the references are listed.被撤回的出版物: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study (Retracted article. See vol. 167, pg. 277, 2022)
Hany M. Dabbous et al.
ARCHIVES OF VIROLOGY (2021)
Role of favipiravir in the treatment of COVID-19
Shashank Joshi et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
Fiona Marra et al.
DRUGS IN R&D (2021)
Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters
Agnes Telbisz et al.
PHARMACEUTICS (2021)
A novel, rapid and simple UPLC-MS/MS method for quantification of favipiravir in human plasma: Application to a bioequivalence study
Mamdouh R. Rezk et al.
BIOMEDICAL CHROMATOGRAPHY (2021)
A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers
Mosaad Morsy et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)
Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
Toshie Manabe et al.
BMC INFECTIOUS DISEASES (2021)
Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients
Zelalem G. Dessie et al.
BMC INFECTIOUS DISEASES (2021)
Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
Yasemin Ozsurekci et al.
PEDIATRIC NEPHROLOGY (2021)
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
Soheil Hassanipour et al.
SCIENTIFIC REPORTS (2021)
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
Du Yin-Xiao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis
Yue Zhou et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Kathleen Chiotos et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2020)
Uric Acid Elevation by Favipiravir, an Antiviral Drug
Eikan Mishima et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus
Sandra L. Bixler et al.
ANTIVIRAL RESEARCH (2018)
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Yousuke Furuta et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)
Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted
Thi Huyen Tram Nguyen et al.
PLOS NEGLECTED TROPICAL DISEASES (2017)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2013)